




PHARMACEUTICAL 2023

CUMBERLAND PHARMACEUTICALS 
INC
 Rank 230 of 446





PHARMACEUTICAL 2023

CUMBERLAND PHARMACEUTICALS INC

Rank 230 of 446



The relative strengths and weaknesses of CUMBERLAND PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CUMBERLAND PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of CUMBERLAND PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 32% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,870
Cost of Goods Sold	9,119
Intangible Assets	31,505
Liabilities, Current	28,580
Liabilities, Non-Current	12,171
Other Assets	15,266
Other Compr. Net Income	0
Other Expenses	22,383
Other Liabilities	16,200
Other Net Income	710
Other Revenues	42,011
Property and Equipment	284
Research and Development	6,689
Selling, General and Administrative Expense	10,180

Output Variable	Value in 1000 USD
Assets	92,925
Liabilities	56,951
Expenses	48,371
Revenues	42,011
Stockholders Equity	35,974
Net Income	-5,650
Comprehensive Net Income	-5,650
Economic Capital Ratio	75%